We are live on ! Find out more
TAK icon

Takeda Pharmaceutical
TAK

315 hedge funds and large institutions have $1.2B invested in Takeda Pharmaceutical in 2025 Q2 according to their latest regulatory filings, with 50 funds opening new positions, 134 increasing their positions, 66 reducing their positions, and 33 closing their positions.

New
Increased
Maintained
Reduced
Closed

12,219% more call options, than puts

Call options by funds: $26.6M | Put options by funds: $216K

103% more repeat investments, than reductions

Existing positions increased: 134 | Existing positions reduced: 66

52% more first-time investments, than exits

New positions opened: 50 | Existing positions closed: 33

14% more capital invested

Capital invested by funds: $1.06B → $1.2B (+$146M)

3% more funds holding

Funds holding: 307 → 315 (+8)

2.02% less ownership

Funds ownership: 4.47% → 2.45% (-2%)

Holders
315
Holders Change
+8
Holders Change %
+2.61%
% of All Funds
4.15%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
50
Increased
134
Reduced
66
Closed
33
Calls
$26.6M
Puts
$216K
Net Calls
+$26.4M
Net Calls Change
+$1.11M

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$42M
2
UBS Group
UBS Group
Switzerland
+$33.5M
3
Morgan Stanley
Morgan Stanley
New York
+$28.3M
4
BlackRock
BlackRock
New York
+$13.6M
5
Bank of America
Bank of America
North Carolina
+$10.6M

Top Sellers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$13.3M
2
VanEck Associates
VanEck Associates
New York
-$12.4M
3
Goldman Sachs
Goldman Sachs
New York
-$12.1M
4
Toronto Dominion Bank
Toronto Dominion Bank
Ontario, Canada
-$9.63M
5
Verition Fund Management
Verition Fund Management
Connecticut
-$6.54M
Name Holding Trade Value Shares
Change 		Change in
Stake
MWA
276
Medallion Wealth Advisors
Connecticut
$2.16K – – –
HFS
277
Hughes Financial Services
Virginia
$2.07K – – –
FMP
278
Financial Management Professionals
Texas
$1.98K – – –
T
279
Tidemark
California
$1.95K – – –
SIS
280
Strategic Investment Solutions
Illinois
$1.93K – – –
MYIA
281
Mount Yale Investment Advisors
Colorado
$1.8K +$1.73K +117 New
AAS
282
Ameritas Advisory Services
Nebraska
$1.7K +$1.63K +110 New
PWA
283
Physician Wealth Advisors
Utah
$1.67K +$621 +42 +64%
WTC
284
WhitTier Trust Company
Nevada
$1.62K -$591 -40 -28%
HPC
285
HM Payson & Co
Maine
$1.55K – – –
EPIMS
286
Evelyn Partners Investment Management Services
$1.51K – – –
AT
287
Arlington Trust
Alabama
$1.39K +$1.33K +90 New
FRA
288
Front Row Advisors
California
$1.33K -$872 -59 -41%
RI
289
Ridgewood Investments
New Jersey
$1.11K – – –
GC
290
Gould Capital
Washington
$1.08K – – –
CI
291
CX Institutional
Indiana
$1K – – –
WA
292
WPG Advisers
Maryland
$974 – – –
BLC
293
Brown, Lisle/Cummings
Rhode Island
$897 – – –
PWAM
294
Private Wealth Asset Management
Iowa
$819 – – –
SIS
295
Sound Income Strategies
Florida
$740 – – –
FG
296
Fairman Group
Pennsylvania
$711 – – –
SL
297
Salomon & Ludwin
Virginia
$632 +$606 +41 New
BA
298
Bellwether Advisors
Nebraska
$557 – – –
CA
299
Clearstead Advisors
Ohio
$387 -$1.39K -94 -79%
AAG
300
Armstrong Advisory Group
Massachusetts
$387 – – –
10 11
12
13 14

TAK Hedge Fund Activity: Q2 2025 in Review

315 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Takeda Pharmaceutical (TAK) for Q2 2025, worth a combined $1.2B — up 14% from $1.06B a quarter earlier.

Buyers outnumbered sellers: 50 funds opened new TAK positions and 33 closed out — a net gain of 17 holders — while 134 added to existing stakes and 66 trimmed.

The largest buyer was Millennium Management, adding an estimated $42M. The largest seller was Adage Capital Partners, cutting an estimated $13.3M.

  • 315 institutional investors held Takeda Pharmaceutical (TAK) as of Q2 2025, up from 307 in Q1 2025.
  • Funds reported $1.2B of Takeda Pharmaceutical stock for Q2 2025, up 14% quarter-over-quarter.
  • 50 funds opened new Takeda Pharmaceutical positions in Q2 2025 and 33 closed out, a net change of +17 holders.
  • The largest Takeda Pharmaceutical buyer in Q2 2025 was Millennium Management, an estimated $42M added.
  • The largest Takeda Pharmaceutical seller in Q2 2025 was Adage Capital Partners, an estimated $13.3M sold.

Based on aggregated 13F filings for Q2 2025.